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The advances in our knowledge of renal hypertension over the last 75 years represents outstanding
accomplishments in experimental and clinical medicine. A review of the highlights of this important
investigation in hypertension should begin with
Tigerstedt and Bergman's work in Scandinavia which
demonstrated in 1898, that extracts of kidney possessed a hypertensive action. They gave the name
"renin" to the impure substance which produced this
effect. For the next 30 years much work was done
on the vasoconstrictor action of extracts of the
adrenal medulla, the nervous system and the kidney.
At the height of the depression, Harry Goldblatt, with a few hundred dollars, began his investigations on the production of hypertension. His
classical report in 1934 gave investigators an easy
method of producing permanent renal hypertension.
He used a tiny adjustable silver clip on the renal
artery of dogs to produce partial or incomplete
ischemia of the kidney. His work was confirmed
promptly by many others.
In 1938, Fasciolo, Houssay and Taquini in
Argentina, by cross-venous techniques, demonstrated
that the ischemic kidney produced a hypertensive
substance, renin. In 1939, Braun Menendez and
his group in Argentina extracted a substance which
they called hypertensin, produced by the incubation of
renin with plasma globulin or hypertensinogen. Page
and Helmer, almost simultaneously in the United
States, reached similar conclusions but used different
terminology, renin plus renin activator produces
angiotonin.
Over the next 15 years much work was done
on these extracts and enzymes. Finally, a decapeptide
substance was identified. In 1956, Skeggs showed
that a converting enzyme made the substance an
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active vasopressor material by splitting off two amino
acids.
A year later, Bumpus in the United States and
Rittel in Switzerland synthesized angiotonin or hypertensin, depending on which group was involved.
A year later, Page and Braun Menendez got together
and came up with the bastard term-angiotensin.
Levels of renin activity in patients were determined
by the bioassay technique perfected by Gunnels until
1969, when Haber described a practical radioimmune assay for angiotensin which has gained wide
acceptance by the medical profession.
On the clinical side, Butler in 1937, published
the first report of nephrectomy for unilateral pyelonephritis with relief of hypertension. This began the
era of nephrectomy for all sorts of diseases with the
hope of relieving hypertension. In 1939, Blackman
examined at time of autopsy renal arteries of 50 patients with so-called hypertension. A high percentage
of arteries (87 % ) had arteriosclerotic plaques and
54% were found to have severe stenosis. This report was not accepted at the time by the profession.
In 1944, Yuile classified renal artery obstruction
occlusive disease into extrinsic and intrinsic types.
Finally in 1948, after many years of indiscriminate
renal sacrifice, Homer Smith laid down the criteria
for cure of hypertension, 145/ 90, and this closed
the era of imprecise diagnosis oi renal hypertension.
In 1950, Parke Smith and Arthur Evans in
Cincinnati published a large series of translumbar
aortograms with a low incidence of complications,
resulting in a wave of popularity for aortography by
urologists and later vascular surgeons. Up to that
time, it had not been widely accepted by the medical
profession in the United States. In 1952, at the
Cleveland Clinic, we began to apply aortography in
hypertensive patients. In 1954, Freeman and his
associates reported the first case of endarterectomy
of the renal artery with relief of hypertension. In
1954, Howard and his colleagues at Johns Hopkins
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published their classical report of cure of hypertension by nephrectomy. They called attention to the
importance of careful scrutiny of the intravenous
pyelogram for renal atrophy and to the fact that
urine from the affected kidney had a lower sodium
concentration and lower urine volume.
In 195 7, the first report on the use of homografts for correcting fibromuscular hyperplasia of
the renal artery appeared. Since then many techniques have evolved for the correction of all kinds of
renal artery disease.
Renin is a proteolytic enzyme with a molecular
weight of about 40,000. Its only known activity is
to break a specific leucine-leucine bond on renin
substrate produced in the liver. Renin originates in
the granular cells surrounding afferent arterioles adjacent to renal glomeruli. These juxtaglomerular
cells, along with a few specialized distal tubular cells
(macula densa) in the same region, form the juxtaglomerular apparatus. This structure may be considered a combination baroceptor and sodium
sensor.
After renin acts on the substrate, angiotensin I is formed. As it passes through the circulation,
it is acted on by the converting enzyme to form
angiotensin II, the vasoconstrictor material causing
arterial constriction and hypertension. Angiotensin
II is also a major stimulus for aldosterone secretion
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by the adrenal gland, providing a feedback mechanism and completing the cycle initiated by renin
release. Renin is inactivated in the liver, and angiotensin II is probably inactivated at its receptive sites.
This is a dynamic, rapidly responding circuit. Renin
is released within a few minutes after appropriate
stimulation. Decline is equally rapid. Among r~cent
discoveries, plasma and tissue enzymes have been
found to exist which are capable of degrading angiotensin I and II to form a hectopeptide which exerts
a powerful influence on the adrenal cortex to secrete
aldosterone and preserve sodium.
We have used Haber's radio-immune assay
technique for the last two and one-half years in Dr.
Wan's biochemical laboratory at Norfolk General
Hospital. This is a specific assay for angiotensin I
generation rate, which in most situations provides a
correct measurement of renin activity. Nearly 400
measurements of plasma renin activity were made
between August 1970 and December 1971; over 900
determinations, which included 56 bilateral renal
vein determinations, were done in 1972. Approximately 20 patients were selected for operation in
1972. In the first two months of 1973, we have
operated on nine patients who have had this investigation recently at Norfolk General Hospital, reflecting in part the increased interest in renal hypertension since the use of renin assays on a wide scale.

